Extended Data Fig. 2: Alternative splicing of KRAS in CRISPR-Cas9 modified PC-9 cells.
From: Silent mutations reveal therapeutic vulnerability in RAS Q61 cancers
a, Images of KRAS-specific PCR amplicons of cDNA, generated from CRISPR-Cas9 modified PC-9 clones expressing different KRAS mutations in the presence or absence of osimertinib given the influence of upstream EGFR signals. Heterozygosity or homozygosity of KRAS mutants is shown for each clone. M: 100 bp-marker, m: mutant, wt: wild-type, fs: frameshift. b, Images of KRAS-specific PCR amplicons of cDNA, generated from additional CRISPR-Cas9 modified PC-9 clones expressing different KRAS mutations. c, Images of KRAS-specific PCR amplicons of cDNA, generated from KRAS mutant cell lines and CRISPR-Cas9 modified PC-9 clones expressing different KRAS mutations.
